Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > BUSINESS
BUSINESS
- DSP to Boost Domestic CNS Business for Early Maximization of Lonasen
November 1, 2011
- Shionogi’s Strength in Japan Weakened by Slack US Results, Overall Sales Down 13.5% in Apr-Sept
November 1, 2011
- Sharp Decrease in Profits due to Declines in License Revenues: JCR’s Half year Financial Report
November 1, 2011
- Zeria Upwardly Revises Profits forecasts for 1st Half of FY2012
November 1, 2011
- Mochida: Epadel, Lexapro Drive Growth in 1st-Half Sales and Profits
November 1, 2011
- DSP: Strong Yen Contributes to 5.6% Decline in Sales
November 1, 2011
- Further Deterioration in Sales Prices Unlikely in 2nd Half: President Watanabe of Mediceo
November 1, 2011
- Three Top Dispensing Pharmacy Chains Report 50% Growth in Operating Profits
November 1, 2011
- ASKA Downwardly Revises Sales Forecast Due to Effects of Quake
October 31, 2011
- Astellas Upwardly Revises Business Forecasts Driven by Vesicare
October 31, 2011
- Abilify Posted US Sales of US$983 Mil. in Jul-Sep
October 31, 2011
- Anti-HIV JTK-303 Applied for Combination Tablet in the US: JT
October 31, 2011
- Losses Increase Due to Fallen Milestone Payments: OncoTherapy
October 31, 2011
- Wakamoto’s Apr-Sep Profits Up 2% on Latanoprost Sales Growth, Recovered Losses
October 31, 2011
- Terumo Posts Record Sales, Operating Profits in First Half FY2012
October 31, 2011
- PI Trial of Darinaparsin Inj. Starts for PTCL: Solasia
October 31, 2011
- MediciNova to Start Repeat Dose PIb Clinical Trial of MN-221 in US
October 31, 2011
- Medipal HD: Near 90% Decline in Operating Profits
October 31, 2011
- Meiji Seika Pharma Planning to Develop Biosimilars for Infectious Diseases, Cancer, and RA
October 31, 2011
- Kyowa Kirin’s Pharmaceutical Business Reports Increases in Sales, Profits in Jan.-Sept. Driven by Nesp
October 28, 2011
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…